- Home
- IKNA
IKNA
Ikena Oncology Inc.
as 07-26-2024 4:00pm EST
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 78.7M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 287.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $5.95 | Next Earning Date: | 08-08-2024 |
| Revenue: | $3,848,000 | Revenue Growth: | -78.07% |
| Revenue Growth (this year): | -61.03% | Revenue Growth (next year): | N/A |
Latest Ikena Oncology Inc. News
IKNA Breaking Stock News: Dive into IKNA Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Best Momentum Stocks to Buy for July 12th
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
AFP
2 months ago
N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
PR Newswire
2 months ago
Enduring role of 'treasuring the past' hailed
Compare IKNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKNA Ikena Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.